Arkolith/Insider Trading/ATOS/Form 4/A

Quay Steven C

President & CEO, DirectorATOSSA THERAPEUTICS, INC. (ATOS) · full profile →Form 4/A · filed Jan 30, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 20, 2026Grant(A)332K—$0346K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 20, 2026Grant(A)950K$0.60$570K950K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001193125-26-030571) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML